Search clinical trials for: Certolizumab Pegol (CDP870)

Total 276 results

UCB Pharma

Completed

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease (Welcome2)

Crohn's Disease

United States, France, Italy, United Kingdom, Belgium, Germany, Spain, Switzerland, Canada, Netherlands, Austria, Sweden
UCB Pharma SA

Completed

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease (PRECiSE 4)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine
UCB Pharma SA

Completed

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] (PRECiSE 3)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine, Canada and more
UCB Pharma

Completed

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

Crohn Disease

United States, Australia, Italy, Ukraine, Germany, Belgium, Israel, Romania, Canada, New Zealand, Brazil, Estonia, Russian Federation, Chile, Austria, Poland, Hungary, Latvia, Czechia, Finland
UCB Pharma

Completed

Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)

Crohn's Disease

Japan
UCB Pharma

Completed

A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)

Crohn's Disease
UCB Pharma

Completed

Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).

Crohn's Disease
UCB Japan Co. Ltd.

Completed

Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease

Crohn's Disease

Japan
UCB Biopharma SRL

Completed

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice (CIMREAL)

Plaque Psoriasis

Belgium, Canada, Czechia, France, Germany, Greece, Italy, Spain, United Kingdom
UCB Pharma

Completed

Comparison Bioequivalence Study: Pre-filled Syringe (Reference) Versus Auto-injection Device (Test)

Healthy

France
UCB Pharma

Completed

Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study (CERTAIN)

Rheumatoid Arthritis

France, Poland, Germany, Austria, Italy
UCB Pharma

Completed

Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease (COSPAR II)

Crohn's Disease

United States, Germany, Canada
UCB Pharma

Completed

Bio-availability Comparison of Three Formulations of Certolizumab Pegol in Healthy Volunteers

Bioavailability Study on Healthy Volunteers

France
UCB Pharma

Completed

Mucosal Healing Study in Crohn's Disease (CD) (MUSIC)

Crohn's Disease

France, Germany, Belgium
UCB Pharma

Completed

Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA) (MARVELOUS)

Rheumatoid Arthritis

Denmark, Netherlands, Poland, Sweden
UCB Pharma

Completed

A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Canada, Belgium, Argentina, Israel, Bulgaria, Chile, Russian Federation, Australia, Czechia, Latvia, Ukraine, Croatia
UCB Pharma

Terminated

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease (COSPAR1)

Crohn's Disease

United States, Germany, Canada
UCB Pharma

Completed

Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab

Crohn's Disease

United States, France, Italy, United Kingdom, Belgium, Germany, Spain, Switzerland, Canada, Netherlands, Denmark, Austria, Norway, Sweden
Nathan Wei, MD, FACP, FACR:
University of California, San Diego

Completed

Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

Rheumatoid Arthritis

United States
Otsuka Pharmaceutical Co., Ltd.
UCB Japan Co. Ltd.

Completed

Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Japan
Astellas Pharma Inc
UCB Japan Co. Ltd.

Completed

Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients

Rheumatoid Arthritis

Japan
UCB Pharma

Completed

Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study (CERTAIN 2)

Rheumatoid Arthritis

Poland, Germany, Austria, France, Italy
UCB Celltech

Terminated

The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents (NURTURE)

Crohn's Disease

United States, Canada, New Zealand, Australia
UCB Biopharma SRL

Completed

A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU (C-VIEW)

Axial Spondyloarthritis (axSpA) | Anterior Uveitis (AU)

Czechia, Germany, Netherlands, Poland, Spain
UCB BIOSCIENCES GmbH
PPD

Completed

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Crohn Disease

Russian Federation, Belgium, United States, Australia, Austria, Brazil, Canada, Czechia, Estonia, Germany, Hungary, Israel, Italy, Latvia, New Zealand, Poland, Romania, Ukraine
UCB Pharma

Completed

Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis

Rheumatoid Arthritis
Otsuka Pharmaceutical Co., Ltd.
UCB Japan Co. Ltd.

Completed

Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Japan
UCB BIOSCIENCES GmbH

Completed

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS (C-AXSPAND)

Axial Spondyloarthritis | Nonradiographic Axial Spondyloarthritis | Nr-axSpA

United States, Australia, Bulgaria, Canada, Czechia, Hungary, Poland, Russian Federation, Taiwan
UCB Pharma SA
Parexel

Completed

A Study of Certolizumab Pegol to Evaluate Pharmacokinetics and Safety in Adult Healthy Chinese Subjects

Healthy Subjects

China
Astellas Pharma Inc
UCB Japan Co. Ltd.

Completed

Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870

Active Rheumatoid Arthritis

Japan
UCB Biopharma SRL

Completed

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

United States, Czechia, Germany, Greece, Moldova, Republic of, Netherlands, Poland, Russian Federation
UCB Biopharma S.P.R.L.

Completed

An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (CIMPASI-1)

Psoriasis | Plaque Psoriasis

United States, Canada, Czechia, Germany, Hungary
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (CIMPASI-2)

Psoriasis | Plaque Psoriasis

United States, Austria, Canada, Poland
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis
UCB Pharma

Withdrawn

Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

Crohn Disease
UCB BIOSCIENCES GmbH
Parexel

Completed

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo (C-OPTIMISE)

Ankylosing Spondylitis | Axial Spondyloarthrithis

United States, Belgium, Bulgaria, Czechia, France, Germany, Hungary, Netherlands, Poland, Romania, Spain, Taiwan, Turkey, United Kingdom
UCB Pharma

Completed

Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis

Arthritis, Rheumatoid
UCB Pharma

Completed

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

Rheumatoid Arthritis

United States
Atlanta Gastroenterology Associates
UCB Pharma

Unknown

Optimizing Cimzia in Crohn's Patients

Crohn's Disease

United States
UCB Pharma

Completed

Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease

Crohn's Disease

Japan
UCB Pharma

Withdrawn

A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease

Crohn's Disease
University of Washington
University of Pennsylvania; UCB Pharma

Completed

Study of Cimzia for the Treatment of Ulcerative Colitis (UC CIMZIA)

Ulcerative Colitis

United States
UCB Pharma

Completed

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (REALISTIC)

Rheumatoid Arthritis

United States, France, Italy, Germany, Spain, Canada, Netherlands
UCB Biopharma S.P.R.L.

Completed

A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Moderate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Japan
UCB Pharma

Completed

A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects (PREDICT)

Rheumatoid Arthritis

United States
Shafran Gastroenterology Center
UCB Pharma

Completed

Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy

Crohn's Disease

United States
UCB Pharma

Completed

Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol

Crohn's Disease

United States, Australia, Canada
ICStudy, LLC
UCB Pharma

Completed

Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

Cystitis, Interstitial

United States
Astellas Pharma Inc
UCB Japan Co. Ltd.

Completed

Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients

Rheumatoid Arthritis

Japan
UCB Pharma

Completed

Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis

Psoriasis

France, Germany

3

Subscribe